These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1149754)

  • 1. Treatment of parkinsonism with l-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study.
    Dietrichson P; Presthus J; Holmsen R
    Eur Neurol; 1975; 13(4):339-49. PubMed ID: 1149754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
    Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
    J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
    Ohmoto T; Kishikawa H
    Folia Psychiatr Neurol Jpn; 1975; 29(1):1-12. PubMed ID: 1158313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
    Dowzenko A; Buksowicz C; Kuran W
    Neurol Neurochir Pol; 1975; 9(4):487-93. PubMed ID: 1165836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 7. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
    Eisenlohr JJ; Gehlen W
    MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699
    [No Abstract]   [Full Text] [Related]  

  • 8. Treating parkinsonism with L-dopa and carboxylase inhibitor.
    Shau-Fong K; Ho YM
    Mod Med Asia; 1977 Sep; 13(9):23-5. PubMed ID: 600260
    [No Abstract]   [Full Text] [Related]  

  • 9. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combined therapy of parkinsonism with bromocriptine, L-dopa and decarboxylase inhibitor (author's transl)].
    Vardy J; Rabey JM; Streifler M
    Harefuah; 1977 Sep; 93(5-6):129-33. PubMed ID: 924233
    [No Abstract]   [Full Text] [Related]  

  • 11. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 13. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 14. Sinemet and the treatment of Parkinsonism.
    Boshes B
    Ann Intern Med; 1981 Mar; 94(3):364-70. PubMed ID: 7013595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison between results achieved by administering L-dopa and Sinemet in parkinsonism in the light of our records].
    Szulc-Kuberska J; Niewodniczy A; Poźniak-Patewics E; Wolczyk-Orzechowska M
    Neurol Neurochir Pol; 1975; 9(5):611-5. PubMed ID: 1186952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [L-dopa + peripheral decarboxylase antagonist].
    Wiesel FA
    Lakartidningen; 1975 Oct; 72(43):4173. PubMed ID: 1177632
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
    Namba S; Omoto T; Kishikawa H
    No To Shinkei; 1976 Aug; 28(8):815-22. PubMed ID: 829033
    [No Abstract]   [Full Text] [Related]  

  • 18. [Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].
    Koziel H; Kuran W; Zakrzewska F
    Neurol Neurochir Pol; 1977; 11(1):73-80. PubMed ID: 840365
    [No Abstract]   [Full Text] [Related]  

  • 19. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new selective suicide inhibitor of peripheral DOPA decarboxylase.
    Wajsbort J; Youdim MB
    Adv Neurol; 1984; 40():251-8. PubMed ID: 6364729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.